levocetirizine dihydrochloride 0.5 MG/ML Oral Solution

What the CMS Formulary Data Shows for levocetirizine dihydrochloride 0.5 MG/ML Oral Solution

Per the CMS 2026 Part D formulary file, levocetirizine dihydrochloride 0.5 MG/ML Oral Solution (RxNorm concept RXCUI 855168, generic name levocetirizine dihydrochloride) appears on 145 distinct formulary files spanning 2,427 Medicare Part D plan offerings - 47.9% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.7.

Real-world access to levocetirizine dihydrochloride 0.5 MG/ML Oral Solution depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 1.4% require step therapy. 44.8% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 642,854 Part D beneficiaries filled levocetirizine dihydrochloride 0.5 MG/ML Oral Solution in 2023, with total plan-and-beneficiary spending of $38,000,182 and an average per-beneficiary annual cost of $59.11. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry levocetirizine dihydrochloride 0.5 MG/ML Oral Solution today.